Date: 2016-11-24
Type of information: Series C financing round
Company: Kymab (UK)
Investors: ORI Fund (China) Hepalink Pharmaceutical (China) Wellcome Trust (UK) Bill & Melinda Gates Foundation (USA) Malin Corporation (UK) CF Woodford Equity Income Fund (UK) Woodford Patient Capital (UK)
Amount: $100 million (£81 million)
Funding type: series C financing round
Planned used: Kymab commenced operations in 2010 and has raised over US$220m of equity financing which includes $100m Series C financing. The company has a pipeline of products in four main therapeutic areas: immuno-oncology; auto-immunity; haematology and infectious disease. Funds will enable Kymab to advance its proprietary pipeline of first-in-class therapeutic human monoclonal antibodies, the first of which is commencing clinical development in 2017.
Others: • On November 24, 2016, Kymab announced that it has successfully secured a US$100 million (£81 million) Series C financing. The financing was led by new investors ORI Healthcare Fund L.P. (“ORI Fund”) with participation by Shenzhen Hepalink Pharmaceutical Co., Ltd (“Hepalink”), as well as follow-on investments from existing shareholders: Wellcome Trust, Bill & Melinda Gates Foundation; Malin Corporation plc; CF Woodford Equity Income Fund and Woodford Patient Capital.
Therapeutic area:
